Last reviewed · How we verify

NCT05900037

GATT-Patch Versus SURGICEL® Original in Minimally Invasive Liver and Gallbladder Surgery

Completed NA Last updated 12 February 2026
What this trial tests

NA trial testing GATT-Patch in Intraoperative Bleeding in 53 participants. Completed in 5 August 2025.

Timeline
2 October 2023
Primary endpoint
7 July 2025
5 August 2025

Quick facts

Lead sponsorGATT Technologies BV
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment53
Start date2 October 2023
Primary completion7 July 2025
Estimated completion5 August 2025
Sites6 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

GATT Technologies BV — full company profile →

Who can join

22 and older, any sex, with Intraoperative Bleeding or Liver Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a pre-market, prospective, randomized (1:1), multicenter, pivotal clinical investigation. The purpose of this investigation is to determine the clinical performance of GATT-Patch as compared with SURGICEL® Original for the management of minimal, mild, or moderate bleeding during minimally invasive liver and gallbladder surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of GATT-Patch

Trials testing the same drug.

Other recruiting trials for Intraoperative Bleeding

Currently open trials in the same condition.

Other GATT Technologies BV trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05900037.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing